The CARMUCI Study Design: A Double‐Blind, Cross‐Over Sham‐Controlled Trial of Indoor Air Purification in People With Cystic Fibrosis and Primary Ciliary Dyskinesia
CARMUCI trial first results are expected in late-2027 and may inform future clinical guidelines and environmental health strategies for managing rare MCC disorders.
Authors
- G Nikolopoulos
- Maria Kakkoura (ORCID: https://orcid.org/0000-0003-3688-1367)
- P Kouis
- Panagiotis Bargiotas (ORCID: https://orcid.org/0000-0001-6502-8942)
- Marina Neophytou (ORCID: https://orcid.org/0000-0001-8393-2441)
- Phivos Ioannou
- Chrysanthi Skevaki (ORCID: https://orcid.org/0000-0001-5194-5635)
- A Michanikou
- Panayiotis K. Yiallouros
- Pinelopi Anagnostopoulou
- Tonia Adamides
- Petros Koutrakis
- Stavroula F. Louka
Institutions
- Harvard University (US)
- Academy of Athens (GR)
- Nicosia General Hospital (CY)
- University of Cyprus (CY)
- Cyprus Research and Innovation Center (Cyprus) (CY)
- Universities of Giessen and Marburg Lung Center (DE)
- Archbishop Makarios III Hospital (CY)
Publication Details
- Journal
- Pediatric Pulmonology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/ppul.71514
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Cyprus
- European Commission
- Stiftung für Pathobiochemie und Molekulare Diagnostik
- Uniklinikum Giessen und Marburg
- Deutsches Zentrum für Lungenforschung
- Horizon 2020 Framework Programme
- HORIZON EUROPE Marie Sklodowska-Curie Actions